Loading...

News & Events

RedDress Receives FDA 510(k) Clearance for RD1 System

Innovative Device for Wound Management

Pardes-Hanna, Israel, June 14, 2018 – RedDress Ltd announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its RD1 system.
RD1 is an innovative wound care product which enables health care providers to produce in real time, in vitro whole blood […]

Wound, Ostomy and Continence Nurses Society (WOCN) 2018

June 3-5 | Philadelphia, PA, USA
Contact us to arrange a meeting at Booth: 947

RedDress RD003 diabetic foot Ulcer study article was published in Apr issue of WOUNDS Journal

RedDress article “Efficacy and Safety of a Novel Autologous Wound Matrix in the Management of Complicated, Chronic Wounds: A Pilot Study” was published in Sep issue of WOUNDS Journal.
http://www.woundsresearch.com/article/safety-and-efficacy-autologous-blood-clot-product-management-texas-1a-or-2a-neuropathic

RedDress has been selected to present a poster at SAWC Fall meeting

RedDress abstract has been accepted as a poster presentation at the 9th Annual Symposium on Advanced Wound Care Fall (SAWC Fall) meeting, October 20-22, 2017, Las Vegas, Nevada

RedDress successfully completes RD003 Clinical Trial

RedDress successfully completes its 20 subject US multicenter RD003 safety trial of the RedDress Wound Care System in Management of Texas 1a or 2a Neuropathic Diabetic Foot Ulcers

RedDress Pilot Clincal Trial article was published in Sep issue of WOUNDS Journal

RedDress article “Efficacy and Safety of a Novel Autologous Wound Matrix in the Management of Complicated, Chronic Wounds: A Pilot Study” was published in Sep issue of WOUNDS Journal.

http://www.woundsresearch.com/article/efficacy-and-safety-novel-autologous-wound-matrix-management-complicated-chronic-wounds

RedDress Enrolls Patients in US RD003 Clinical Trial

For more detail contact us